 | • レポートコード：MRC2304F013 • 出版社/出版日：360iResearch / 2022年10月 • レポート形態：英語、PDF、221ページ • 納品方法：Eメール（受注後2-3日） • 産業分類：医薬品 |
| Single User（1名利用、印刷可） | ￥742,350 (USD4,949) | ▷ お問い合わせ |
| Enterprise License（企業利用、印刷可） | ￥1,492,350 (USD9,949) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 360iResearch社の本調査レポートによると、2021年に7,834.49百万ドルであった世界の医薬品安全性市場規模は2022年に9,513.26百万ドルになり、更に年平均21.60％拡大して2027年までに25,334.85百万ドルに達する見通しです。本書は、医薬品安全性の世界市場についての多面的な調査を元に、序論、調査方法、エグゼクティブサマリー、市場概要、市場インサイト、機能別（ADR報告、医薬品安全監査、完全統合ソフトウェア、問題追跡）分析、デリバリー方式別（オンデマンド、オンプレミス）分析、エンドユーザー別（BPO、CRO、製薬＆バイオテクノロジー企業）分析、地域別（南北アメリカ、アメリカ、カナダ、ブラジル、アジア太平洋、日本、中国、インド、韓国、台湾、ヨーロッパ/中東/アフリカ、イギリス、ドイツ、フランス、ロシア、その他）分析、競争状況、企業情報などの内容をまとめた市場調査レポートです。なお、本書に掲載されている企業情報には、AB CUBE、Accenture, Inc.、Anju Software Inc.、ArisGlobal LLC(Nordic Capital)、Cinven、Cognizant Technology Solutions Corp、Ergomed PLC、EXTEDO GmbH、Genpact、HCL Technologies Limited、Indigene Pharmaceuticals, Inc.などが含まれています。 ・序論 ・調査方法 ・エグゼクティブサマリー ・市場概要 ・市場インサイト ・世界の医薬品安全性市場規模：機能別 - ADR報告機能の市場規模 - 医薬品安全監査機能の市場規模 - 完全統合ソフトウェアの市場規模 - 問題追跡機能の市場規模 ・世界の医薬品安全性市場規模：デリバリー方式別 - オンデマンドの市場規模 - オンプレミスの市場規模 ・世界の医薬品安全性市場規模：エンドユーザー別 - BPOにおける市場規模 - CROにおける市場規模 - 製薬＆バイオテクノロジー企業における市場規模 ・世界の医薬品安全性市場規模：地域別 - 南北アメリカの医薬品安全性市場規模 アメリカの医薬品安全性市場規模 カナダの医薬品安全性市場規模 ブラジルの医薬品安全性市場規模 ... - アジア太平洋の医薬品安全性市場規模 日本の医薬品安全性市場規模 中国の医薬品安全性市場規模 インドの医薬品安全性市場規模 韓国の医薬品安全性市場規模 台湾の医薬品安全性市場規模 ... - ヨーロッパ/中東/アフリカの医薬品安全性市場規模 イギリスの医薬品安全性市場規模 ドイツの医薬品安全性市場規模 フランスの医薬品安全性市場規模 ロシアの医薬品安全性市場規模 ... - その他地域の医薬品安全性市場規模 ・競争状況 ・企業情報 |
The Global Drug Safety Market size was estimated at USD 7,834.49 million in 2021 and expected to reach USD 9,513.26 million in 2022, and is projected to grow at a CAGR 21.60% to reach USD 25,334.85 million by 2027.
Market Statistics:
The report provides market sizing and forecast across 7 major currencies – USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.
Market Segmentation & Coverage:
This research report categorizes the Drug Safety to forecast the revenues and analyze the trends in each of the following sub-markets:
Based on Functionality, the market was studied across ADR Reporting, Drug Safety Audits, Fully Integrated Software, and Issue Tracking.
Based on Delivery Mode, the market was studied across On-demand and On-premise.
Based on End User, the market was studied across BPOs, CROs, and Pharma & biotech companies.
Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.
Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.
Cumulative Impact of 2022 Russia Ukraine Conflict:
We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Drug Safety market considering the current update on the conflict and its global response.
Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.
FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Drug Safety Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.
Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.
Competitive Scenario:
The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.
Company Usability Profiles:
The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Drug Safety Market, including AB CUBE, Accenture, Inc., Anju Software Inc., ArisGlobal LLC(Nordic Capital), Cinven, Cognizant Technology Solutions Corp, Ergomed PLC, EXTEDO GmbH, Genpact, HCL Technologies Limited, Indigene Pharmaceuticals, Inc., IQVIA Inc., Medco Health Solutions, Inc., Nordic Capital, Oracle Corporation, Parexel International Corporation, Pharmaceutical Product Development, LLC, PRA Health Sciences, Inc., Sarjen Systems Pvt. Ltd, Sparta Systems Inc., Syneos Health, Inc., Telerx, Umbra Global LLC, and Worldwide Clinical Trials.
The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments
The report answers questions such as:
1. What is the market size and forecast of the Global Drug Safety Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Drug Safety Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Drug Safety Market?
4. What is the competitive strategic window for opportunities in the Global Drug Safety Market?
5. What are the technology trends and regulatory frameworks in the Global Drug Safety Market?
6. What is the market share of the leading vendors in the Global Drug Safety Market?
7. What modes and strategic moves are considered suitable for entering the Global Drug Safety Market?
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing population addicted to smoking
5.1.1.2. Escalating patient safety issues
5.1.2. Restraints
5.1.2.1. Issues related to clinical trials
5.1.3. Opportunities
5.1.3.1. Rising R&D activities
5.1.3.2. Increasing adoption of drug safety facilitating the launch of new drugs
5.1.4. Challenges
5.1.4.1. Adverse effects of drugs
5.2. Cumulative Impact of COVID-19
6. Drug Safety Market, by Functionality
6.1. Introduction
6.2. ADR Reporting
6.3. Drug Safety Audits
6.4. Fully Integrated Software
6.5. Issue Tracking
7. Drug Safety Market, by Delivery Mode
7.1. Introduction
7.2. On-demand
7.3. On-premise
8. Drug Safety Market, by End User
8.1. Introduction
8.2. BPOs
8.3. CROs
8.4. Pharma & biotech companies
9. Americas Drug Safety Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Drug Safety Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam
11. Europe, Middle East & Africa Drug Safety Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom
12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.1.1. Quadrants
12.1.2. Business Strategy
12.1.3. Product Satisfaction
12.2. Market Ranking Analysis, By Key Player
12.3. Market Share Analysis, By Key Player
12.4. Competitive Scenario
12.4.1. Merger & Acquisition
12.4.2. Agreement, Collaboration, & Partnership
12.4.3. New Product Launch & Enhancement
12.4.4. Investment & Funding
12.4.5. Award, Recognition, & Expansion
13. Company Usability Profiles
13.1. AB CUBE
13.1.1. Business Overview
13.1.2. Key Executives
13.1.3. Product & Services
13.2. Accenture, Inc.
13.2.1. Business Overview
13.2.2. Key Executives
13.2.3. Product & Services
13.3. Anju Software Inc.
13.3.1. Business Overview
13.3.2. Key Executives
13.3.3. Product & Services
13.4. ArisGlobal LLC(Nordic Capital)
13.4.1. Business Overview
13.4.2. Key Executives
13.4.3. Product & Services
13.5. Cinven
13.5.1. Business Overview
13.5.2. Key Executives
13.5.3. Product & Services
13.6. Cognizant Technology Solutions Corp
13.6.1. Business Overview
13.6.2. Key Executives
13.6.3. Product & Services
13.7. Ergomed PLC
13.7.1. Business Overview
13.7.2. Key Executives
13.7.3. Product & Services
13.8. EXTEDO GmbH
13.8.1. Business Overview
13.8.2. Key Executives
13.8.3. Product & Services
13.9. Genpact
13.9.1. Business Overview
13.9.2. Key Executives
13.9.3. Product & Services
13.10. HCL Technologies Limited
13.10.1. Business Overview
13.10.2. Key Executives
13.10.3. Product & Services
13.11. Indigene Pharmaceuticals, Inc.
13.11.1. Business Overview
13.11.2. Key Executives
13.11.3. Product & Services
13.12. IQVIA Inc.
13.12.1. Business Overview
13.12.2. Key Executives
13.12.3. Product & Services
13.13. Medco Health Solutions, Inc.
13.13.1. Business Overview
13.13.2. Key Executives
13.13.3. Product & Services
13.14. Nordic Capital
13.14.1. Business Overview
13.14.2. Key Executives
13.14.3. Product & Services
13.15. Oracle Corporation
13.15.1. Business Overview
13.15.2. Key Executives
13.15.3. Product & Services
13.16. Parexel International Corporation
13.16.1. Business Overview
13.16.2. Key Executives
13.16.3. Product & Services
13.17. Pharmaceutical Product Development, LLC
13.17.1. Business Overview
13.17.2. Key Executives
13.17.3. Product & Services
13.18. PRA Health Sciences, Inc.
13.18.1. Business Overview
13.18.2. Key Executives
13.18.3. Product & Services
13.19. Sarjen Systems Pvt. Ltd
13.19.1. Business Overview
13.19.2. Key Executives
13.19.3. Product & Services
13.20. Sparta Systems Inc.
13.20.1. Business Overview
13.20.2. Key Executives
13.20.3. Product & Services
13.21. Syneos Health, Inc.
13.21.1. Business Overview
13.21.2. Key Executives
13.21.3. Product & Services
13.22. Telerx
13.22.1. Business Overview
13.22.2. Key Executives
13.22.3. Product & Services
13.23. Umbra Global LLC
13.23.1. Business Overview
13.23.2. Key Executives
13.23.3. Product & Services
13.24. Worldwide Clinical Trials
13.24.1. Business Overview
13.24.2. Key Executives
13.24.3. Product & Services
14. Appendix
14.1. Discussion Guide
14.2. License & Pricing